Renovaro Inc

NASDAQ:RENBUnited States

Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.

Contact Information

Headquarters

Century City Medical Plaza 2080 Century City East, Suite 906LOS ANGELES, CA, United States 90067

Phone

212-763-0184

Fax

845-818-3588

Executives

Independent Chairman of the Board

Rene Sindlev

Chief Executive Officer, Principal Executive Officer

Mark Dybul

Interim Chief Financial Officer

Simon Tarsh

Chief Operating Officer

Francois Binette

Lead Independent Director

Gregg Alton